| 0.383 -0.09 (-18.98%) | 08-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.71  |
1-year : | 0.91 |
| Resists | First : | 0.6 |
Second : | 0.78 |
| Pivot price | 0.55 |
|||
| Supports | First : | 0.32 |
Second : | 0.27 |
| MAs | MA(5) : | 0.46 |
MA(20) : | 0.59 |
| MA(100) : | 1.75 |
MA(250) : | 2.34 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2  |
| %K %D | K(14,3) : | 10.7 |
D(3) : | 6.8 |
| RSI | RSI(14): 17.3 |
|||
| 52-week | High : | 13.5 | Low : | 0.32 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BIAF ] has closed below the lower bollinger band by 4.6%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ BIAF ] is to continue within current trading range. It is unclear right now based on current values. 74.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 28 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.46 - 0.47 | 0.47 - 0.47 |
| Low: | 0.32 - 0.32 | 0.32 - 0.33 |
| Close: | 0.38 - 0.39 | 0.39 - 0.39 |
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Thu, 13 Aug 2026
bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules - Business Wire
Fri, 07 Aug 2026
bioAffinity Technologies, Inc. Q2 2026: Revenue $1.51M, EPS $(0.64) — 10-Q Summary - TradingView
Fri, 07 Aug 2026
bioAffinity Technologies reports Q2 2026 revenue $1.51M, net loss $3.37M, cash $2.43M - TradingView
Fri, 07 Aug 2026
bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung - Business Wire
Fri, 07 Aug 2026
Press Release: BioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath(R) Lung - Moomoo
Sat, 01 Aug 2026
bioAffinity Technologies Faces Nasdaq Delisting Risk After Notice - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 6.61e+006 (%) |
| Held by Institutions | 1.8 (%) |
| Shares Short | 363 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.192e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -257.4 % |
| Operating Margin | -220.8 % |
| Return on Assets (ttm) | -125.2 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 5.9e+006 % |
| Gross Profit (p.s.) | 0.29 |
| Sales Per Share | 0.9 |
| EBITDA (p.s.) | -1.77 |
| Qtrly Earnings Growth | -4.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.42 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 522560 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|